NCT05932641 is a Phase 1 clinical trial of AZD3152 (Cohort 1) in COVID-19, SARS-CoV-2, sponsored by AstraZeneca.

Who is sponsoring NCT05932641?

NCT05932641 is sponsored by AstraZeneca.

What drugs are being tested in NCT05932641?

Interventions in NCT05932641: AZD3152 (Cohort 1), Placebo (Cohort 1), AZD3152 (Cohort 2), Placebo (Cohort 2), AZD3152 (Cohort 3), Placebo (Cohort 3).

What condition does NCT05932641 study?

NCT05932641 studies COVID-19, SARS-CoV-2.

Is NCT05932641 still recruiting?

NCT05932641 is currently completed. Last updated 27 December 2024.

Last reviewed 2024-12-27 · How we verify

NCT05932641

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of AZD3152 Intramuscular Injection or Intravenous Infusion in Healthy Japanese Adult Participants

Completed Phase 1 Last updated 27 December 2024

What this trial tests

Phase 1 trial testing AZD3152 (Cohort 1) in COVID-19, SARS-CoV-2 in 24 participants. Completed in 5 December 2024.

Timeline

31 July 2023

Primary endpoint
5 December 2024

5 December 2024

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	24
Start date	31 July 2023
Primary completion	5 December 2024
Estimated completion	5 December 2024
Sites	1 location across Japan

Drugs / interventions tested

AZD3152 (Cohort 1) — full drug profile →
Placebo (Cohort 1)
AZD3152 (Cohort 2)
Placebo (Cohort 2)
AZD3152 (Cohort 3)
Placebo (Cohort 3)

Conditions studied

COVID-19, SARS-CoV-2 — all drugs for COVID-19, SARS-CoV-2 →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 55, any sex, with COVID-19, SARS-CoV-2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

AZD3152 is being evaluated for administration to prevent COVID-19. This Phase I study will gather important information on the safety and tolerability of AZD3152 as well as relevant data on the PK, PD (as the neutralising responses against SARS-CoV-2) profile and the generation of ADA to AZD3152.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05932641 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 27 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05932641.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing